Update shared on 20 Oct 2025
Fair value Increased 1.54%Improved Diagnostics And Genomics Will Broaden Treatment Access
Analysts have raised their price target for Amicus Therapeutics from $15.36 to $15.60 per share, citing an improved revenue growth outlook, higher profit margin estimates, and recent positive developments in the company's intellectual property litigation.
Analyst Commentary
Recent analyst updates highlight a mix of optimism and lingering caution regarding Amicus Therapeutics’ future prospects. The company has seen solid support based on intellectual property developments and updated financial projections, although some uncertainties remain in the path ahead.
Bullish Takeaways- Bullish analysts upgraded their rating to Buy, citing strengthened prospects for Amicus’ lead asset following progress in patent litigation.
- Improved revenue growth outlook and higher margin expectations have driven valuation targets higher, supporting share price upside.
- There is increasing confidence in Amicus’ ability to reach favorable outcomes in ongoing legal cases. This may facilitate settlements and reduce risk.
- Discounted cash flow models imply notable intrinsic value, especially if exclusivity for key products is maintained into the next decade.
- Some caution persists around the timing of legal resolutions. Ongoing trials introduce uncertainty to execution and future cash flow stability.
- Analysts note that despite upgrades, the current share price trades at a significant discount to fundamentals, reflecting market skepticism about full value realization.
- There is ongoing concern about the potential for generic competition over the longer term, which could pressure growth rates and margins if exclusivity ends sooner than forecast.
What's in the News
- Presented new 4-year data from the PROPEL open-label extension study, which showed sustained muscle function and biomarker improvements in adults with late-onset Pompe disease treated with cipaglucosidase alfa-atga plus miglustat (Key Developments).
- Reported that 95% of patients completed the PROPEL clinical trial, supporting the long-term tolerability and efficacy of its lead therapy (Key Developments).
- Reiterated financial guidance for full year 2025, projecting total revenue growth of 15% to 22% and positive GAAP net income during the second half of 2025 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased slightly, moving from $15.36 to $15.60 per share.
- The Discount Rate has risen modestly from 7.06% to 7.12%.
- The Revenue Growth projection has increased from 20.23% to 20.91%.
- The Net Profit Margin estimate has improved from 22.84% to 23.75%.
- The forecast for the future P/E ratio has declined from 28.11x to 27.02x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.